News
GPCR
54.13
+1.12%
0.60
J.P. Morgan Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 3d ago
Weekly Report: what happened at GPCR last week (0810-0814)?
Weekly Report · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/10 12:20
Guggenheim Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/10 11:35
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
TipRanks · 08/10 11:00
Weekly Report: what happened at GPCR last week (0803-0807)?
Weekly Report · 08/10 09:08
SA Asks: What's the outlook for Big Pharma M&A?
Seeking Alpha · 08/08 19:28
Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target
TipRanks · 08/07 20:28
Structure Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 08/07 20:19
Structure Therapeutics Price Target Cut to $97.00/Share From $100.00 by Citigroup
Dow Jones · 08/07 20:19
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97
Benzinga · 08/07 20:09
Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/07 19:15
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Stifel Nicolaus
TipRanks · 08/07 18:25
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/07 15:27
Structure Therapeutics Is Maintained at Market Outperform by Citizens
Dow Jones · 08/07 15:04
Structure Therapeutics Price Target Cut to $110.00/Share From $113.00 by Citizens
Dow Jones · 08/07 15:04
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
Benzinga · 08/07 14:54
Structure Therapeutics price target raised to $111 from $101 at Canaccord
TipRanks · 08/07 11:30
Structure Therapeutics price target lowered to $97 from $100 at Citi
TipRanks · 08/07 10:45
Structure Therapeutics Earns Buy Rating as Lead Oral GLP‑1 Obesity Drug Enters Phase III and Pipeline, Commercial Leadership Bolster Growth Outlook
TipRanks · 08/07 03:55
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.